Literature DB >> 25535200

Spectrum of infections and outcome among hospitalized South Africans with systemic lupus erythematosus.

Thozama Dubula1, Girish M Mody.   

Abstract

Our aim was to determine reasons for admission, the prevalence and spectrum of infections, and the outcomes in a multiethnic cohort of hospitalized systemic lupus erythematosus (SLE) patients in Durban, South Africa. We reviewed the records of hospitalized SLE patients seen over a 79-month period; the demographic data, clinical manifestations, laboratory findings, reasons for admission, nature of infection, and outcome were recorded. Our 167 patients, comprising 59.3% Indians, 33.5% African Blacks, 5.4% Coloreds, and 1.8% Whites, had 327 admissions. Active disease and infections accounted for 218 (66.7%) and 115 (35.2%) admissions respectively, with 58 (17.7%) due to both active disease and infection. Features of active disease were mucocutaneous 33.0%, hematological 30.3%, renal 28.9%, and vasculitis 27.1%. Overall, 83 patients (49.7%) had 155 infections; pneumonia (36.8%), cutaneous sepsis (18.1%), tuberculosis (13.5%), urinary tract infections (12.9%), and septicemia (7.1%) were the most common. The organisms commonly isolated were Staphylococcus aureus 25.4%, Escherichia coli 20.3%, and Klebsiella species and Mycobacterium tuberculosis in 13.6% each. Serositis (odds ratio (OR) = 2.7, p = 0.005) and seizures (OR = 4.8, p = 0.007) were associated with increased risk of infection. Twenty-four (14.4%) patients died from infection and active disease; the patients who died had higher SLEDAI scores (p = 0.02) and longer duration of hospitalization (p = 0.03) but no significant associations on multiple logistic regression analysis. Bacterial infections, including tuberculosis, are common in SLE, and they are a major cause of mortality.

Entities:  

Mesh:

Year:  2014        PMID: 25535200     DOI: 10.1007/s10067-014-2847-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  32 in total

1.  Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT).

Authors:  A J Swaak; H van de Brink ; R J Smeenk; K Manger; J R Kalden; S Tosi; A Marchesoni; Z Domljan; B Rozman; D Logar; G Pokorny; L Kovacs; A Kovacs; P G Vlachoyiannopoulos; H M Moutsopoulos; H Chwalinska-Sadowska; B Dratwianka; E Kiss; N Cikes; B Anic; M Schneider; R Fischer; S Bombardieri; M Mosca; W Graninger; J S Smolen
Journal:  Rheumatology (Oxford)       Date:  2001-01       Impact factor: 7.580

Review 2.  Concomitant systemic lupus erythematosus and HIV: case series and literature review.

Authors:  Girish M Mody; Neeta Patel; Amritha Budhoo; Thozama Dubula
Journal:  Semin Arthritis Rheum       Date:  2014-05-09       Impact factor: 5.532

3.  Prognostic indicators of hospitalized patients with systemic lupus erythematosus: a large retrospective multicenter study in China.

Authors:  Xuebing Feng; Yaohong Zou; Wenyou Pan; Xiangdang Wang; Min Wu; Miaojia Zhang; Juan Tao; Yu Zhang; Kuiling Tan; Jin Li; Zhiwei Chen; Xiang Ding; Xian Qian; Zhanyun Da; Meimei Wang; Lingyun Sun
Journal:  J Rheumatol       Date:  2011-04-01       Impact factor: 4.666

4.  Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus.

Authors:  Su Jin Jeong; Heekyung Choi; Han Sung Lee; Sang Hoon Han; Bum Sik Chin; Ji-Hyeon Baek; Chang Oh Kim; Jun Yong Choi; Young Goo Song; June Myung Kim
Journal:  Scand J Infect Dis       Date:  2009

5.  Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality.

Authors:  F Goldblatt; S Chambers; A Rahman; D A Isenberg
Journal:  Lupus       Date:  2009-07       Impact factor: 2.911

6.  Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

Review 7.  An update on mortality in systemic lupus erythematosus.

Authors:  A Ippolito; M Petri
Journal:  Clin Exp Rheumatol       Date:  2008 Sep-Oct       Impact factor: 4.473

8.  Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality.

Authors:  M Abu-Shakra; M B Urowitz; D D Gladman; J Gough
Journal:  J Rheumatol       Date:  1995-07       Impact factor: 4.666

9.  High mortality with systemic lupus erythematosus in hospitalized African blacks.

Authors:  G M Mody; K B Parag; B C Nathoo; D J Pudifin; J Duursma; Y K Seedat
Journal:  Br J Rheumatol       Date:  1994-12

Review 10.  The geoepidemiology of systemic lupus erythematosus.

Authors:  Andrea T Borchers; Stanley M Naguwa; Yehuda Shoenfeld; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2009-12-24       Impact factor: 9.754

View more
  11 in total

Review 1.  [Systemic lupus erythematosus : Unusual cutaneous manifestations].

Authors:  T Stockinger; L Richter; M Kanzler; M Melichart-Kotik; H Pas; K Derfler; E Schmidt; K Rappersberger
Journal:  Hautarzt       Date:  2016-12       Impact factor: 0.751

2.  All-cause hospitalizations in systemic lupus erythematosus from a single medical center in Israel.

Authors:  Ofer Levy; Andrey Markov; Yulia Drob; Ilia Maslakov; Moshe Tishler; Mirit Amit-Vazina
Journal:  Rheumatol Int       Date:  2018-08-27       Impact factor: 2.631

3.  Clinical characteristics and risk factors of infections in patients with systemic lupus erythematosus.

Authors:  Chengcheng Hou; Ou Jin; Xi Zhang
Journal:  Clin Rheumatol       Date:  2018-07-09       Impact factor: 2.980

4.  Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality.

Authors:  C L Teh; S A Wan; G R Ling
Journal:  Clin Rheumatol       Date:  2018-04-18       Impact factor: 2.980

5.  Non-tuberculous mycobacterium bacteraemia in a pregnant systemic lupus erythematosus (SLE) patient: a case review and pooled case analysis.

Authors:  Syahrul Sazliyana Shaharir; Narisa Sulaiman Sahari; Zeena Mohamed Fuad; Wan Zul Haikal Wan Zukiman; Nurul Hafizah Mohd Yusof; Anita Sulong; Petrick Periasamy
Journal:  Clin Rheumatol       Date:  2017-10-03       Impact factor: 2.980

6.  Hospital-acquired infection in patients with systemic lupus erythematosus: a case-control study in a southern Chinese population.

Authors:  Zhongping Zhan; Minxi Lao; Fan Su; Dongying Chen; Liuqin Liang; Xiuyan Yang
Journal:  Clin Rheumatol       Date:  2017-11-27       Impact factor: 3.650

7.  Epidemiological data on systemic lupus erythematosus in native sub-Saharan Africans.

Authors:  Mickael Essouma; Jan René Nkeck; Francky Teddy Endomba; Jean Joel Bigna; Madeleine Singwe-Ngandeu; Eric Hachulla
Journal:  Data Brief       Date:  2019-11-27

Review 8.  Bacterial infections in lupus: Roles in promoting immune activation and in pathogenesis of the disease.

Authors:  Michael Battaglia; Lee Ann Garrett-Sinha
Journal:  J Transl Autoimmun       Date:  2020-12-23

9.  Rapid and precise diagnosis of pneumonia coinfected by Pneumocystis jirovecii and Aspergillus fumigatus assisted by next-generation sequencing in a patient with systemic lupus erythematosus: a case report.

Authors:  Yili Chen; Lu Ai; Yingqun Zhou; Yating Zhao; Jianyu Huang; Wen Tang; Yujian Liang
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-06-26       Impact factor: 3.944

Review 10.  Global epidemiology of systemic lupus erythematosus.

Authors:  Megan R W Barber; Cristina Drenkard; Titilola Falasinnu; Alberta Hoi; Anselm Mak; Nien Yee Kow; Elisabet Svenungsson; Jonna Peterson; Ann E Clarke; Rosalind Ramsey-Goldman
Journal:  Nat Rev Rheumatol       Date:  2021-08-03       Impact factor: 32.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.